{"id":"W4376609298","doi":"10.1038/s41591-023-02347-y","title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":270,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Clinical endpoint; Medicine; Pembrolizumab; Oncolytic virus; Oncology; Internal medicine; Hazard ratio; Phases of clinical research; Confidence interval; Clinical trial; Immunotherapy; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009111039,0.0002706812,0.000390998,0.0003918268,0.00006720119,0.00001197034,0.0003990874,0.0004949285,0.0002161171],"category_scores_gemma":[0.0004031396,0.0001957651,0.0001038458,0.0009419596,0.0001702889,0.000004079775,0.00008367166,0.0007913742,0.00006266406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001236473,"about_ca_system_score_gemma":0.0003302002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001663805,"about_ca_topic_score_gemma":0.0006000909,"domain_scores_codex":[0.9976902,0.0002116034,0.000372644,0.0005712754,0.0005981564,0.0005561424],"domain_scores_gemma":[0.9990086,0.00006508218,0.00008486746,0.0005657183,0.00009293028,0.0001828216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4149739,0.0004059324,0.00001805463,0.00004272676,0.00009215091,0.0001588684,0.0002872962,0.00004097126,0.5000189,0.00002517265,0.02943107,0.05450498],"study_design_scores_gemma":[0.4363909,0.1049098,0.0001727313,0.0002395621,0.00004200814,0.00004630176,0.0002372108,0.001459822,0.2458913,0.0002785162,0.2096616,0.0006703302],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899855,0.00445834,0.00002375695,0.002830778,0.0008743588,0.001048918,0.00002027634,0.00005816725,0.0006998611],"genre_scores_gemma":[0.9926767,0.001528064,0.00001448924,0.0009634568,0.002305767,0.0001844148,0.0002086385,0.00006207821,0.002056352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2541276,"threshold_uncertainty_score":0.7983069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02117879798470894,"score_gpt":0.389980995708235,"score_spread":0.368802197723526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}